Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Actavis Inc. (NYSE: ACT) shares increased 0.76 percent to close at $145.10 a share Tuesday. The stock traded between $142.26 and $145.76 on volume of 1.77 million shares traded. The company announced that it has completed its acquisition of Warner Chilcott plc. Shares of Actavis have gained approximately 68.0 percent year-to-date.
Get more information on Actavis free access to the in-depth equity report at:
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares surged 21.43 percent to close at $2.89 a share Tuesday. The stock traded between $2.82 and $3.18 on volume of 11.57 million shares traded. The company announced that LX4211, a treatment for Type 2 diabetes, met its primary endpoint in a recent study. Shares of Lexicon Pharmaceuticals have gained approximately 30.0 percent year-to-date.
Get more information on Lexicon Pharmaceuticals and free access to the in-depth equity report at:
Merck & Co., Inc. (NYSE: MRK) shares increased 2.38 percent to close at $48.74 a share Tuesday. The stock traded between $48.15 and $49.23 on volume of 27.34 million shares traded. The company announced plans to cut an additional 8,500 jobs, bring the total to roughly 81,000. Shares of Merck & Co. have gained approximately 19.0 percent year-to-date.
Get more information on Merck & Co. and free access to the in-depth equity report at:
Walgreen Company (NYSE: WAG) shares increased 4.54 percent to close at $56.24 a share Tuesday. The stock traded between $54.11 and $56.69 on volume of 13.71 million shares traded. The company reported sales were a record $72.2 billion for fiscal 2013, compared to $71.6 billion a year ago. Shares of Walgreens have gained approximately 52.0 percent year-to-date.
Get more information on Walgreens and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...